<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227654</url>
  </required_header>
  <id_info>
    <org_study_id>14-GYN-200</org_study_id>
    <nct_id>NCT02227654</nct_id>
  </id_info>
  <brief_title>Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors</brief_title>
  <official_title>Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frederick R. Ueland, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lucille P. Markey Cancer Center at University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present investigation will prospectively evaluate whether serial transvaginal&#xD;
      ultrasonography with Morphology Index (MI) can further reduce false positive results by more&#xD;
      accurately distinguishing benign from malignant ovarian tumors. If there is no change in the&#xD;
      detection of true positive cases, the result will be an increase in the positive predictive&#xD;
      value of ovarian cancer screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To determine if a treatment algorithm using serial transvaginal ultrasound with a tumor&#xD;
      morphology index can improve the positive predictive value (PPV) of ovarian cancer screening&#xD;
      compared to a historical control from 15% to 25%.&#xD;
&#xD;
      Secondary Objective To measure the compliance for study participants enrolled on the&#xD;
      treatment algorithm using serial transvaginal ultrasound with a tumor morphology index.&#xD;
&#xD;
      Exploratory Objective To determine the effectiveness of a treatment algorithm that combines&#xD;
      serum biomarkers aloneor in combination with transvaginal ultrasound to reduce the false&#xD;
      positive rate of ovarian cancer screening in the subset of women agreeing to biomarker&#xD;
      collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive predictive value (PPV) of ovarian cancer screening</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Whether the treatment algorithm for patients with abnormal ultrasounds improves the positive predictive value of ultrasounds as ovarian screening tests, thus lowering the false positive rate compared to historical controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Surgical complications including type, severity, and resolution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to the treatment algorithm</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of required visits that were attended for each individual's treatment algorithm</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3290</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Abnormal Ovarian Ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abnormal Ovarian Ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Abnormal Ovarian Ultrasound</intervention_name>
    <description>Ultrasound</description>
    <arm_group_label>Abnormal Ovarian Ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women must be enrolled in the University of Kentucky Ovarian Cancer Screening Program&#xD;
             Eligibility criteria for the OCSP are: 50 years of age or older, or be postmenopausal&#xD;
             and have not had a prior salpingo-oophorectomy or have a family history of ovarian&#xD;
             cancer in a primary relative or have a self-history of breast cancer.&#xD;
&#xD;
          -  Patients have a documented ovarian abnormality on ultrasound&#xD;
&#xD;
          -  Patients having undergone prior hysterectomy will be eligible provided that they meet&#xD;
             the other requirements for entry into this study.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are not enrolled in the University of Kentucky Ovarian Cancer Screening&#xD;
             Program .&#xD;
&#xD;
          -  Patients who cannot tolerate the vaginal ultrasound procedure.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Patients who are referred with pelvic symptoms, a known pelvic mass, or a history of&#xD;
             prior radiation, will be excluded from this investigation.&#xD;
&#xD;
          -  History of ovarian cancer.&#xD;
&#xD;
          -  Prior bilateral salpingo-oophorectomy.&#xD;
&#xD;
          -  Prisoners.&#xD;
&#xD;
          -  Women who are currently pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Because ovarian cancer is a disease of only women, men are not included in this study, but women of all races and ethnic groups are eligible for this trial.</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick R. Ueland, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Markey Cancer Center, University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederick R. Ueland, M.D.</last_name>
    <phone>859 257-1613</phone>
    <email>fuela0@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Markey Cancer Center, University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frederick R. Ueland, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Frederick R. Ueland, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ovary</keyword>
  <keyword>Cancer</keyword>
  <keyword>Morphology</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

